Biognosys and the Michael J. Fox Foundation for Parkinson’s Research (MJFF) announced a collaboration to develop targeted biomarker assays for LRRK2, a major genetic driver of late-onset Parkinson’s disease. The project will use SISCAPA and TrueSignature targeted proteomics approaches to measure LRRK2 protein levels with sensitivity suitable for translational research. The work is designed to support MJFF’s LRRK2 Investigative Therapeutics Exchange (LITE), a multi-partner framework that brings academic, industry, and clinical participants together. Biognosys said the assay efforts aim to provide reliable tools for measuring target engagement and biological response to de-risk clinical development. The agreement reinforces growing emphasis on proteomics-based pharmacodynamic biomarkers to help separate mechanistic activity from downstream clinical effects.